Fermenta Biotech FY26 Revenue ₹547.8 Cr; Core Business Grows 27%

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorKavya Nair|Published at:
Fermenta Biotech FY26 Revenue ₹547.8 Cr; Core Business Grows 27%
Overview

Fermenta Biotech reported FY26 revenue of ₹547.8 crore. Excluding a ₹43 crore drop in real estate income, the core business grew 27% year-on-year to ₹546 crore. Profitability improved with EBITDA margins maintained at 22.3%.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Fermenta Biotech FY26 Results

Fermenta Biotech reported FY26 consolidated revenue of ₹547.8 crore and Profit After Tax (PAT) of ₹70.3 crore. Diluted Earnings Per Share (EPS) stood at ₹24.51.

Reader Takeaway: Strong core growth and improved cash flow offset one-time real estate income decline.

What just happened

The company announced its financial results for the fiscal year 2026. Total revenue was ₹547.8 crore. EBITDA stood at ₹122.2 crore, with an EBITDA margin of 22.3%, which is noted to be well above FY23-24 levels.

Why this matters

The results highlight a significant recovery and growth in Fermenta Biotech's core nutrition business. The year-on-year growth in core revenue, excluding the impact of real estate value unlocking, demonstrates the operational strength of the company's segments.

The backstory

FY26 performance needs to be viewed against a high FY25 base, partly due to real estate value unlocking. This non-core income contributed ₹45 crore in FY25 but reduced to ₹2 crore in FY26. The core business, however, showed substantial growth.

What changes now

Fermenta Biotech's financial agility has improved. Free cash flow more than tripled to ₹62 crore, driven by better operating cash flow conversion. Total debt remains stable at ₹109 crore, while cash reserves grew by 30% to ₹92 crore.

Risks to watch

The primary watch point is the headline revenue growth, which is impacted by the significant reduction in one-time real estate income. Investors should focus on the sustainability of core business performance.

Peer comparison

  • The Vitamin D3 Human Nutrition segment revenue reached ₹293 crore (+28% YoY).
  • The Animal Nutrition segment revenue reached ₹109 crore (+32% YoY).

Context metrics (time-bound)

  • FY26 Total Revenue: ₹547.8 crore
  • FY26 Revenue (Ex-Real Estate): ₹546 crore
  • FY26 EBITDA: ₹122.2 crore
  • FY26 PAT: ₹70.3 crore
  • FY26 Free Cash Flow: ₹62 crore
  • FY26 Cash Reserves: ₹92 crore

What to track next

Investors should monitor the continued growth momentum in the Vitamin D3 segments for both human and animal nutrition, and the company's ability to maintain its improved operating efficiencies and profitability.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.